Clinton Health Access Initiative

Today is . SCD is one of the most common and most painful genetic disorders in the world, yet it remains chronically underfunded and overlooked. In Ghana alone, an estimated 18,000 babies are born with the disease every year. Up to 90% of them may die before age five. Not because treatment doesn't exist, but because they won't get screened in time.

That's exactly why we made screening a focus of our program.

With catalytic funding from Coefficient Giving, we've been able to demonstrate what's possible: 50,000 test kits donated, 66,800 more on the way, and a program projected to save over 1,500 lives. But proof-of-concept isn't enough. The goal has always been to move this into Ghana's national health system, fully implemented, fully covered, no out-of-pocket costs for families.

That's what we're building toward. Because children with sickle cell disease need systems that show up for them.

Gates Foundation

Today at , six countries — Ethiopia, Ghana, Honduras, Nigeria, Senegal, and Zambia — pledged over US$185 million to expand access to contraceptives and life-saving maternal and newborn health supplies.

It's one of the largest recent government financing commitments for reproductive and maternal health and it's not a coincidence that the number matches the US$185 million gap in contraceptive funding that aid cuts are projected to leave in 2026 alone.

Alongside these commitments, CHAI, Unitaid, and UNFPA are launching a new market-shaping partnership to expand access to the calibrated drape, a low-cost device that helps health workers detect postpartum hemorrhage early and trigger timely treatment. Postpartum hemorrhage is a leading cause of maternal death worldwide.

https://ow.ly/Ovw250Z3bX0

, a twice-yearly injectable HIV prevention drug, is now reaching people in low- and middle-income countries. A new flash market update tracks where rollout stands and what comes next.

• Eight African countries have introduced lenacapavir for PrEP
• More than 11,000 people initiated so far
• Across all ten early adopter countries, more than 600,000 people are projected to start lenacapavir this year
• Fourteen more countries are planning launches by end of 2026 or early 2027

The report also tracks progress toward generic market entry — which will be critical to bring costs down and reach the people who need it most. https://ow.ly/BE1550Z2onB

Wits RHI, Unitaid